TOKYO ( TheStreet) -- Astellas Pharma , the No. 2 drugmaker in Japan, reached an agreement to acquire OSI Pharmaceuticals ( OSIP) for $4 billion.

Astellas increased its offer for OSI to $57.50 a share, up from $52 the Japanese company had offered in March. The offer is a premium of 55% to the $37.02 closing price of OSI on Feb. 26, the last trading day Astellas announced its bid.

OSI shares closed Friday at $59.80.

OSI's drug line-up includes the blockbuster cancer drug Tarceva, which had $1.2 billion in sales in 2009.

"The merger with OSI provides Astellas with a top-tier oncology platform in the U.S. and an expanded product portfolio and pipelines," said Masafumi Nogimori, president and CEO of Astellas in a statement Monday.

-- Reported by Joseph Woelfel in New York.

Follow TheStreet.com on Twitter and become a fan on Facebook.

If you liked this article you might like

Allos: Folotyn Survival Trend in Lung Cancer

Allos: Folotyn Survival Trend in Lung Cancer

Empire State Index: Monday's Headlines

Empire State Index: Monday's Headlines

OSI Pharma, Biogen, Teva Rise to Highs

OSI Pharma, Biogen, Teva Rise to Highs

Bristol-Myers: Analysts' Upgrades, Downgrades

Bristol-Myers: Analysts' Upgrades, Downgrades